Topline PhIII data bode well as Lilly's dulaglutide girds for diabetes battle
This article was originally published in Scrip
Executive Summary
Eli Lilly reported topline data from three Phase III clinical trials that showed the higher of two once-weekly doses for the long-acting glucagon-like peptide 1 (GLP-1) analogue dulaglutide (LY2189265) met the trials' primary endpoints, while both the 0.75mg and 1.5mg doses were statistically superior to three other drugs in the treatment of type 2 diabetes.